- KEI comments on MPP consultation regarding mandate to expand into HCV (and other diseases).
- Five groups ask USTR to protect orphan works in TPP
- IMS Health May 2015 comments on patient access to oncology drugs
- Switzerland pressures Colombia to deny compulsory license on imatinib
- 17 WTO Members (Brazil, China, India, Russia) submit draft Ministerial Decision on Non-Violation and Situation Complaints
- KEI briefing note on the evolution of TPP negotiating text on patentable subject matter
- Seminars on Drug Pricing: Part 3, Aidan Hollis
- KEI's second installment of TPP IP Chapter leak, includes copyright, all other provisions
- Knowledge Ecology International Leaks TPP Text on Intellectual Property
- WTO Trade Policy Review of India- EU, Japan, Switzerland and the US question India over Section 3(d) and Compulsory Licensing
16-18 February 2015 WIPO Expert Forum on International Technology Transfer to examine Alternatives to the Patent SystemSubmitted by thiru on 10. February 2015 - 8:59
The World Intellectual Property Organization (WIPO) will host an Expert Forum on International Technology Transfer on 16 February 2015 to 18 February 2015 at its New Conference Hall. The event is open to the public, and the link for online registration can be found here: http://www.wipo.int/meetings/en/registration/form.jsp?meeting_id=35562.
Attached is a leaked version of Japan's October 3, 2014 proposals for intellectual property for the Regional Comprehensive Economic Partnership.
The Regional Comprehensive Economic Partnership (RCEP) is a proposed free trade agreement (FTA) between the ten member states of the Association of Southeast Asian Nations (ASEAN) (Brunei, Burma (Myanmar), Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam) and the six states with which ASEAN has existing FTAs (Australia, China, India, Japan, South Korea and New Zealand).
Attached are KEI's February 6 comments to USTR on the 2015 Special 301.
Our 7 page submission begins with this:
Attached are KEI's January 30, 2015 comments on the India IP Policy.
This is how the comments begin:
Knowledge Ecology International (KEI) has reviewed the document entitled “National IPR Policy” prepared by the IPR Think Tank. The document is surprisingly lacking in several key areas. In particular:
Today, on World Cancer Day, there has been many great announcements and celebrations.
The FDA approved Pfizer's new drug Ibrance (INN: palbociclib) for the treatment of metastatic (advanced) breast cancer to be used in combination with letrozole based on a 165 person trial at UCLA's cancer center. (FDA press release here, ABC story here.)
WTO TRIPS Council (February 2015): Norway and the United States bring gender mainstreaming to the fore-Women and InnovationSubmitted by thiru on 4. February 2015 - 4:45
The first session of the 2015 World Trade Organization's TRIPS Council takes place from 24 February 2015 to 25 February 2015. Like clockwork, the United States has tabled the inclusion of an additional item on Intellectual Property and Innovation. This marks the 8th time since November 2012 that the United States has submitted the inclusion of an additional agenda item to the TRIPS Council relating to intellectual property or innovation.
February 4, 2015 is World Cancer Day. The rapidly increasing cost of cancer drugs should be broadly discussed. The Union for Affordable Cancer Treatment (UACT), a union of people affected by cancer (http://cancerunion.org/) is asking the author and co-author of the "Tufts Cost Study," --a not-yet-released "study" used to justify high prices of drugs without providing data-- to address the following questions:
EB 136 Draft decision passed on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual PropertySubmitted by Claire Cassedy on 3. February 2015 - 10:58
On Tuesday February 3, 2015, the final day of the 136th WHO Executive Board meeting, the EB passed a draft decision on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPoA). The draft decision recommends to the WHA that the GSPOA be extended until 2022.
EB 136 Friday, January 30th: Discussion of Consultative Expert Working Group on Research Development-Financing and CoordinationSubmitted by Claire Cassedy on 31. January 2015 - 3:35
Another matter considered during the Friday, January 30th session of the WHO Executive Board was the "Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination." In addition to the general report on the CEWG, the EB also considered the Director General's report on the CEWG "Health research and development demonstration projects."
EB 136 Friday, January 30th: Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual PropertySubmitted by Claire Cassedy on 30. January 2015 - 11:25
On Friday, January 30th, the WHO Executive Board discussed the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA). The discussion covered several documents in relation to the GSPoA, including:
EB 136 Tuesday January 28: WHO Engagement with Non-state Actors; US issues apology to the African GroupSubmitted by Claire Cassedy on 28. January 2015 - 5:24
During Tuesday's session of the WHO Executive Board, the board considered a proposal from Argentina on the table for a "Framework of Engagement with Non-state Actors." Many states, both Board members and non-Executive Board member states, contributed to the discussion, citing the issue as a critical reform issue for the WHO. While a number of states took issue with some of the specifics of the draft proposal, for example that at current time all types of non-state actors were lumped together (i.e.
Argentina, Brazil, India and South Africa- Draft decision to extend mandate of Global Strategy and Plan of Action till 2022Submitted by thiru on 27. January 2015 - 3:36
On Tuesday, 27 January 2015, Argentina, Brazil, India and South Africa tabled a draft decision to extend the mandate of the Global strategy and plan of action and public health, innovation and intellectual property (EB136/CONF.7) until 2022. We expect that this draft decision will be discussed on Thursday, 29 January 2015 under agenda item 10.5, Global strategy and plan of action on public health, innovation and intellectual property.
On Sunday January 25, 2015, the WHO Executive Board unanimously approved the resolution, "Ebola: Ending the current outbreak, strengthening global preparedness, and ensuring WHO capacity to prepare for and respond to future large-scale outbreaks and emergencies with health consequences." Though unanimous in the end, negotiations for the resolution took 4 days, the Friday session lasting until 5:45am on Saturday morning.
WTO TRIPS Council (October 2014): Bangladesh statement (on behalf of LDCs)- Extension of the 2016 transition periodSubmitted by thiru on 13. January 2015 - 8:16
At the WTO TRIPS Council in October 2014, Bangladesh, on behalf of the LDC Group, delivered the following intervention on "Extension of the Transition Period Under Article 66.1 of the TRIPS Agreement for Least-Developed Country Members for Certain Obligations with Respect to Pharmaceutical Products." The current transition period incorporate two WTO decisions, TRIPS Council decision, IP/C/25 (Extension of the Transition Period under Article 66.1 of the TRIPS Agreement for Least-Developed Country Members for Certain Obligat
In May 2014, the World Health Organization's member countries passed decision 67(15) instructing WHO Director-General Margaret Chan to explore, with TDR, the possibility of hosting a pooled funding mechanism for R&D.